drugset / Trial / NCT05603312
A Double-blind Study to Evaluate the Safety of Glutamic Acid Decarboxylase Gene Transfer in Parkinson's Participants
RandomizedParallel-groupTriple-blindTreatment
Summary
The objective of this clinical trial was to evaluate the safety and tolerability of adeno-associated virus (AAV)-mediated delivery of glutamic acid decarboxylase (GAD) gene transfer into the subthalamic nuclei (STN) of participants with Parkinson's Disease.
Timeline
- Start
- 2022-10-05
- Primary completion
- 2024-09-06
- Completion
- 2024-09-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AAV-GAD | Gene therapy (AAV / viral vector) | — | Other |